Differential effects of enalapril–felodipine versus enalapril–lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension
Scanty information is available on the effects of combination drug treatment based on an ACE inhibitor and a calcium channel blocker on the neurometabolic alterations characterizing obesity-related hypertension (OHT). After 2-week run-in with enalapril (20 mg), 36 OHTs were randomized according to a double-blind crossover design to a combination therapy with either lercanidipine 10 mg (L) or felodipine extended release 5 mg (F), each lasting 8 weeks. Measurements included clinic and ambulatory blood pressure (BP) and heart rate, homeostasis model assessment index, plasma norepinephrine, and muscle sympathetic nerve activity.
Source: Journal of the American Society of Hypertension - Category: Cardiology Authors: Gino Seravalle, Gianmaria Brambilla, Daniela Prata Pizzalla, Anna Casati, Marta Riva, Cesare Cuspidi, Michele Bombelli, Giuseppe Mancia, Guido Grassi Tags: Research Article Source Type: research
More News: Calcium | Cardiology | Eating Disorders & Weight Management | Enalapril | Felodipine | Heart | Hypertension | Neurology | Obesity | PET Scan | Reflex Sympathetic Dystrophy